Takara Bio Inc
TSE:4974
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
941
1 276
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Takara Bio Inc
Takara Bio Inc
Total Equity
Takara Bio Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Takara Bio Inc
TSE:4974
|
Total Equity
¥111.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
GNI Group Ltd
TSE:2160
|
Total Equity
¥36.8B
|
CAGR 3-Years
27%
|
CAGR 5-Years
30%
|
CAGR 10-Years
23%
|
|
|
PeptiDream Inc
TSE:4587
|
Total Equity
¥58.5B
|
CAGR 3-Years
33%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Total Equity
¥11.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
22%
|
CAGR 10-Years
12%
|
|
|
S
|
StemRIM Inc
TSE:4599
|
Total Equity
¥8.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cuorips Inc
TSE:4894
|
Total Equity
¥6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Takara Bio Inc
Glance View
Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,539 full-time employees. The company went IPO on 2004-12-07. The firm operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
See Also
What is Takara Bio Inc's Total Equity?
Total Equity
111.2B
JPY
Based on the financial report for Jun 30, 2024, Takara Bio Inc's Total Equity amounts to 111.2B JPY.
What is Takara Bio Inc's Total Equity growth rate?
Total Equity CAGR 10Y
7%
Over the last year, the Total Equity growth was 3%. The average annual Total Equity growth rates for Takara Bio Inc have been 11% over the past three years , 11% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
